MCID: AST007
MIFTS: 63

Astrocytoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Astrocytoma

MalaCards integrated aliases for Astrocytoma:

Name: Astrocytoma 12 29 52 42 14 69
Cerebral Astrocytoma 12 69
Astrocytoma, No Icd-O Subtype 12
Astrocytoma of Cerebrum 12
Astrocytoma of Brain 12
Astrocytic Tumor 12
Astroglioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3069
MeSH 42 D001254

Summaries for Astrocytoma

Disease Ontology : 12 A malignant glioma that is has material basis in astocyte cells, a type of star-shaped glial cell, located in the cerebrum.

MalaCards based summary : Astrocytoma, also known as cerebral astrocytoma, is related to pilocytic astrocytoma of cerebellum and mixed oligodendroglioma-astrocytoma. An important gene associated with Astrocytoma is IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic), and among its related pathways/superpathways are ERK Signaling and Phospholipase-C Pathway. The drugs Afinitor and Temodar have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells, and related phenotypes are Decreased cell migration and Decreased sensitivity to paclitaxel

Wikipedia : 72 Astrocytomas are a type of cancer of the brain. They originate in a particular kind of glial cells,... more...

Related Diseases for Astrocytoma

Diseases in the Astrocytoma family:

Juvenile Astrocytoma

Diseases related to Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 409)
id Related Disease Score Top Affiliating Genes
1 pilocytic astrocytoma of cerebellum 34.4 IDH1 KIAA1549 TP53
2 mixed oligodendroglioma-astrocytoma 34.1 IDH1 TP53
3 pineal gland astrocytoma 33.9 IDH1 KIAA1549 NF1
4 grade iii astrocytoma 33.6 CDK4 EGFR GFAP IDH1 MGMT NES
5 juvenile astrocytoma 33.4 EGFR GFAP IDH1 MDM2 MGMT PTEN
6 diencephalic astrocytomas 32.5 CDK4 CDKN2A GFAP IDH1 KIAA1549 KRAS
7 brain stem astrocytic neoplasm 32.3 GFAP NF1 TP53
8 glioblastoma 3 31.9 DMBT1 GFAP MGMT NES TP53
9 anaplastic oligodendroglioma 31.1 GFAP MDM2 PTEN
10 gliofibroma 30.8 GFAP IDH1 MGMT TP53
11 autoimmune lymphoproliferative syndrome 30.2 GFAP NF1 PTEN TP53
12 prostate cancer 29.2 CCND1 CDK4 EGFR KRAS MDM2 PTEN
13 giant cell glioblastoma 28.4 CCND1 CDK4 CDKN2A DMBT1 EGFR GFAP
14 colorectal cancer 28.2 CCND1 CDK4 CDKN2A EGFR ITGB1 KRAS
15 adult astrocytic tumour 28.1 CCND1 CDK4 CDKN2A DMBT1 EGFR GFAP
16 pilocytic astrocytoma 12.3
17 fibrillary astrocytoma 12.3
18 subependymal giant cell astrocytoma 12.2
19 spinal cord astrocytoma 11.9
20 cerebellar astrocytoma 11.9
21 gemistocytic astrocytoma 11.9
22 pilomyxoid astrocytoma 11.9
23 protoplasmic astrocytoma 11.9
24 juvenile pilocytic astrocytoma 11.9
25 childhood pilocytic astrocytoma 11.8
26 optic nerve astrocytoma 11.8
27 desmoplastic infantile astrocytoma 11.8
28 desmoplastic infantile astrocytoma/ganglioglioma 11.8
29 childhood cerebral astrocytoma 11.7
30 childhood optic tract astrocytoma 11.7
31 mixed astrocytoma-ependymoma 11.7
32 cauda equina intradural extramedullary astrocytoma 11.6
33 adult brainstem astrocytoma 11.6
34 childhood brainstem astrocytoma 11.6
35 mixed astrocytoma-ependymoma-oligodendroglioma 11.6
36 cerebellar astrocytoma, childhood 11.6
37 melanoma and neural system tumor syndrome 11.6
38 glioma susceptibility 1 11.4
39 li-fraumeni syndrome 11.2
40 tuberous sclerosis 11.2
41 glioblastoma multiforme 11.2
42 diencephalic syndrome 11.1
43 pancoast tumor 11.0 GFAP TP53
44 cervical adenoid cystic carcinoma 11.0 CDKN2A TP53
45 breast myoepithelial neoplasm 11.0 KRAS PTEN TP53
46 adenocarcinoma in situ 11.0 CDKN2A KRAS TP53
47 esophagus squamous cell carcinoma 11.0 CDKN2A PTEN TP53
48 pediatric infratentorial ependymoma 11.0 EGFR TP53
49 pleomorphic xanthoastrocytoma 11.0
50 iodine hypothyroidism 11.0 GFAP IDH1 TP53

Graphical network of the top 20 diseases related to Astrocytoma:



Diseases related to Astrocytoma

Symptoms & Phenotypes for Astrocytoma

GenomeRNAi Phenotypes related to Astrocytoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.35 CDK4 EGFR ITGB1 KRAS NF1
2 Decreased sensitivity to paclitaxel GR00112-A-0 8.62 NF1 PTEN

MGI Mouse Phenotypes related to Astrocytoma:

44 (show all 27)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.5 MDM2 NF1 NRN1 OLIG2 PTEN TP53
2 behavior/neurological MP:0005386 10.48 PTEN TP53 VEGFA CCND1 CDK4 CDKN2A
3 growth/size/body region MP:0005378 10.47 CCND1 CDK4 CDKN2A EGFR GFAP IDH1
4 homeostasis/metabolism MP:0005376 10.44 CCND1 CDK4 CDKN2A DMBT1 EGFR GFAP
5 digestive/alimentary MP:0005381 10.42 VEGFA CCND1 CDK4 CDKN2A DMBT1 EGFR
6 cardiovascular system MP:0005385 10.41 CCND1 CDK4 CDKN2A EGFR GFAP ITGB1
7 mortality/aging MP:0010768 10.41 IDH1 ITGB1 KRAS MDM2 MGMT NF1
8 immune system MP:0005387 10.4 CCND1 CDK4 CDKN2A DMBT1 EGFR GFAP
9 endocrine/exocrine gland MP:0005379 10.38 CCND1 CDK4 CDKN2A EGFR ITGB1 KRAS
10 embryo MP:0005380 10.35 CDK4 CDKN2A DMBT1 EGFR ITGB1 KRAS
11 hematopoietic system MP:0005397 10.35 VEGFA CCND1 CDK4 CDKN2A EGFR IDH1
12 neoplasm MP:0002006 10.32 CCND1 CDK4 CDKN2A DMBT1 EGFR ITGB1
13 nervous system MP:0003631 10.3 CDKN2A EGFR GFAP ITGB1 KRAS MDM2
14 integument MP:0010771 10.29 KRAS MDM2 NF1 PTEN TP53 VEGFA
15 muscle MP:0005369 10.27 MDM2 NF1 CDK4 CDKN2A EGFR GFAP
16 craniofacial MP:0005382 10.22 CCND1 EGFR ITGB1 KRAS MDM2 NF1
17 liver/biliary system MP:0005370 10.22 ITGB1 KRAS MDM2 NF1 PTEN TP53
18 limbs/digits/tail MP:0005371 10.14 EGFR ITGB1 KRAS MDM2 NF1 PTEN
19 normal MP:0002873 10.14 CCND1 CDK4 EGFR GFAP ITGB1 KRAS
20 no phenotypic analysis MP:0003012 10.09 CDKN2A EGFR KRAS MDM2 MGMT NRN1
21 hearing/vestibular/ear MP:0005377 10.06 DMBT1 EGFR ITGB1 KRAS NF1 TP53
22 pigmentation MP:0001186 10.02 CDK4 CDKN2A EGFR ITGB1 KRAS MDM2
23 renal/urinary system MP:0005367 10.02 CDK4 DMBT1 EGFR ITGB1 KRAS MDM2
24 reproductive system MP:0005389 9.96 CCND1 CDK4 CDKN2A EGFR ITGB1 KRAS
25 respiratory system MP:0005388 9.93 CCND1 CDKN2A EGFR IDH1 ITGB1 KRAS
26 skeleton MP:0005390 9.73 OLIG2 PTEN TP53 VEGFA CCND1 CDKN2A
27 vision/eye MP:0005391 9.4 ITGB1 KRAS NF1 OLIG2 PTEN TP53

Drugs & Therapeutics for Astrocytoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 46 EVEROLIMUS Novartis March 2009
2
Temodar 17 46 TEMOZOLOMIDE Schering-Plough August 1999

Drugs for Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 593)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
3
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1 159351-69-6 6442177
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
5
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
6
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
7 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
8 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
10 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
11 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1
12 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
13 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
14
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 498142 38904
15
Cyclophosphamide Approved, Investigational Phase 2, Phase 3, Phase 1 50-18-0, 6055-19-2 2907
16
Etoposide Approved Phase 2, Phase 3, Phase 1 33419-42-0 36462
17
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
18 Thiotepa Approved Phase 2, Phase 3, Phase 1 52-24-4 5453
19
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
20
Tranexamic Acid Approved Phase 3 1197-18-8 5526
21
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
22
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
23
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
24
Lomustine Approved Phase 3,Phase 2,Phase 1 13010-47-4 3950
25
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
26
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
27
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
28
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
29
Procarbazine Approved Phase 3,Phase 2,Phase 1 671-16-9 4915
30
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
31
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
32
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
33
Bevacizumab Approved, Investigational Phase 2, Phase 3, Phase 1, Early Phase 1 216974-75-3
34
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702
35
Aminolevulinic acid Approved Phase 3,Phase 1,Phase 2 106-60-5 137
36
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
37
Hydroxychloroquine Approved Phase 2, Phase 3,Phase 1 118-42-3 3652
38
Thioguanine Approved Phase 3,Phase 2 154-42-7 2723601
39
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
40
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
41
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
42
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
43
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
44
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
45
Ondansetron Approved Phase 3 99614-02-5 4595
46
Donepezil Approved Phase 3,Phase 2,Early Phase 1 120014-06-4 3152
47
chloroquine Approved, Vet_approved Phase 3,Phase 2,Phase 1 54-05-7 2719
48
Leflunomide Approved, Investigational Phase 3,Phase 2 75706-12-6 3899
49
Copper Approved Phase 2, Phase 3,Phase 1,Early Phase 1 7440-50-8 27099
50
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4

Interventional clinical trials:

(show top 50) (show all 1353)

id Name Status NCT ID Phase Drugs
1 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
2 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
3 Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301 Active, not recruiting NCT02338609 Phase 4 Everolimus;Envirolimus drug class as prescribed by Physician
4 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Not yet recruiting NCT03297125 Phase 4
5 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
6 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
7 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
8 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
9 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
10 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
11 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
12 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
13 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
14 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
15 Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Completed NCT00789828 Phase 3 Everolimus;Placebo
16 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3 Temozolomide;Semustine
17 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3 Temozolomide
18 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
19 Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
20 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
21 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
22 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
23 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
24 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
25 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
26 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
27 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
28 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
29 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
30 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
31 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
32 An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies Completed NCT00226655 Phase 3 hCRF [XERECEPT (corticorelin acetate injection)]
33 XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors Completed NCT00088166 Phase 3 hCRF;placebo hCRF
34 Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Completed NCT00790400 Phase 3 Everolimus (RAD001);Everolimus Placebo
35 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
36 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
37 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
38 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
39 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
40 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3 Temozolomide
41 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
42 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
43 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed NCT00777153 Phase 3 Cediranib;Cediranib;Lomustine Chemotherapy;Placebo Cediranib
44 Nimotuzumab in Adults With Glioblastoma Multiforma Completed NCT00753246 Phase 3 nimotuzumab
45 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
46 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3 temozolomide
47 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Completed NCT00379470 Phase 3
48 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
49 Enzastaurin Versus Lomustine in Glioblastoma Completed NCT00295815 Phase 3 enzastaurin;lomustine
50 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3 Chloroquine

Search NIH Clinical Center for Astrocytoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: astrocytoma

Genetic Tests for Astrocytoma

Genetic tests related to Astrocytoma:

id Genetic test Affiliating Genes
1 Astrocytoma 29

Anatomical Context for Astrocytoma

MalaCards organs/tissues related to Astrocytoma:

39
Brain, Spinal Cord, T Cells, Endothelial, Bone, Testes, Breast

Publications for Astrocytoma

Articles related to Astrocytoma:

(show top 50) (show all 2241)
id Title Authors Year
1
Cathepsin L silencing increases As2O3 toxicity in malignantly transformed pilocytic astrocytoma MPA58 cells by activating caspases 3/7. ( 28412241 )
2017
2
Diffuse Infiltrating Oligodendroglioma and Astrocytoma. ( 28640702 )
2017
3
Correlative analyses of the expression levels of PIAS3, p-SHP2, SOCS1 and SOCS3 with STAT3 activation in human astrocytomas. ( 28035384 )
2017
4
Native Oligodendrocytes in Astrocytomas Might Inhibit Tumor Proliferation by WIF1 Expression. ( 28040794 )
2017
5
Vascular Endothelial Growth Factor as an Angiogenic Marker in Malignant Astrocytoma and Oligodendroglioma: An Indian Scenario. ( 28384867 )
2017
6
Midbrain Gliofibroma Presenting in Adulthood following "Cure" of a Childhood Intraventricular Pilocytic Astrocytoma. ( 28245445 )
2017
7
The Mystery of Multiple Masses: A Case of Anaplastic Astrocytoma. ( 28775924 )
2017
8
Solitary primary leptomeningeal astrocytoma - An extremely rare pathology. ( 28681779 )
2017
9
Hydrocephalus associated with spinal intramedullary pilocytic astrocytoma. ( 28484535 )
2017
10
Targeting CD133 improves chemotherapeutic efficacy of recurrent pediatric pilocytic astrocytoma following prolonged chemotherapy. ( 28137267 )
2017
11
Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. ( 28870792 )
2017
12
Nucleolar and spindle associated protein 1 promotes the aggressiveness of astrocytoma by activating the Hedgehog signaling pathway. ( 28899410 )
2017
13
Prognostic value of survivin and DNA topoisomerase III+ in diffuse and anaplastic astrocytomas. ( 28214203 )
2017
14
Antia89inflammatory actions of gabapentin and pregabalin on the substance Pa89induced mitogena89activated protein kinase activation in U373 MG human glioblastoma astrocytoma cells. ( 28849160 )
2017
15
Spinal Cord Astrocytoma with Isocitrate Dehydrogenase 1 Gene Mutation. ( 28866063 )
2017
16
Unusual Occurrence of Multifocal Desmoplastic Infantile Astrocytoma: A Case Report and Review of the Literature. ( 28222441 )
2017
17
Eya2 overexpression promotes the invasion of human astrocytoma through the regulation of ERK/MMP9 signaling. ( 28901379 )
2017
18
Pilocytic Astrocytoma Enlargement Following Irradiation: Relapse or Pseudoprogression? ( 28367384 )
2017
19
Recurrent Optic Nerve Pilocytic Astrocytoma: A Rare Case. ( 28658822 )
2017
20
Methylation profiling of paediatric pilocytic astrocytoma reveals variants specifically associated with tumour location and predictive of recurrence. ( 28388012 )
2017
21
Evaluation of outcomes after stereotactic radiosurgery for pilocytic astrocytoma. ( 28567590 )
2017
22
Desmoplastic infantile astrocytoma and ganglioglioma: case report and review of the literature. ( 27668845 )
2017
23
Adult pilocytic astrocytoma of conus medullaris: clinical considerations and review of the literature. ( 28425761 )
2017
24
Longitudinal mutational analysis of a cerebellar pilocytic astrocytoma recurring as a ganglioglioma. ( 27718322 )
2017
25
A dangerous liaison: Leptin and sPLA2-IIA join forces to induce proliferation and migration of astrocytoma cells. ( 28249041 )
2017
26
Retinal astrocytoma in a dog. ( 28878413 )
2017
27
Benefit with adjuvant chemotherapy in anaplastic astrocytoma. ( 28801187 )
2017
28
Retinal Metastases From Anaplastic Astrocytoma. ( 28864383 )
2017
29
Isolated Trochlear Palsy Due to Pilocytic Astrocytoma Involving the Pineal Gland. ( 28831788 )
2017
30
Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation. ( 28074282 )
2017
31
Fluorescence guided resection with 5-aminolevulinic acid of a pilomyxoid astrocytoma of the third ventricle. ( 28495088 )
2017
32
Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus. ( 28511812 )
2017
33
Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma. ( 28791452 )
2017
34
Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history. ( 28699883 )
2017
35
Pilocytic astrocytoma mimicking cavernous angioma: Imaging features and histological characteristics. ( 28919136 )
2017
36
Synchronous gemistocytic astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p/19q-codeleted in a patient with CCDC26 polymorphism. ( 28550371 )
2017
37
Interferon (IFN)-induced protein 35 (IFI35) negatively regulates IFN-I^-phosphorylated STAT1-RIG-I-CXCL10/CCL5 axis in U373MG astrocytoma cells treated with polyinosinic-polycytidylic acid. ( 28109979 )
2017
38
A Case of Leptomeningeal Dissemination of Pilocytic Astrocytoma in a Child. ( 28446265 )
2017
39
Axial MR diffusion tensor imaging and tractography in clinical diagnosed and pathology confirmed cervical spinal cord astrocytoma. ( 28320182 )
2017
40
Subependymal Giant Cell Astrocytoma Presenting with Tumoral Bleeding: A Case Report. ( 28516078 )
2017
41
Intramedullary Thoracic Spine Astrocytoma Presenting as Hydrocephalus in an Infant: A Case Report. ( 28848162 )
2017
42
Correction: A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma. ( 28880959 )
2017
43
A Novel Variant of OCT4 Entitled OCT4B3 is Expressed in Human Bladder Cancer and Astrocytoma Cell Lines. ( 28706610 )
2017
44
Everolimus Alleviates Obstructive Hydrocephalus due to Subependymal Giant Cell Astrocytomas. ( 28162859 )
2017
45
Posterior fossa pilomyxoid astrocytoma with spontaneous hemorrhage in pediatric patients. ( 28741227 )
2017
46
Bevacizumab Therapy for Pilomyxoid Astrocytoma. ( 28338567 )
2017
47
Pilocytic astrocytoma: A rare presentation as intraventricular tumor. ( 28680735 )
2017
48
Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex. ( 28866062 )
2017
49
A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma. ( 28448514 )
2017
50
A germline deletion of 9p21.3 presenting as familial melanoma, astrocytoma and breast cancer: clinical and genetic counselling challenges. ( 28754699 )
2017

Variations for Astrocytoma

ClinVar genetic disease variations for Astrocytoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
2 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
3 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
4 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
5 FGFR1 NM_023110.2(FGFR1): c.1638C> A (p.Asn546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs779707422 GRCh37 Chromosome 8, 38274849: 38274849
6 FGFR1 NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869320694 GRCh37 Chromosome 8, 38272308: 38272308
7 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
8 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113

Cosmic variations for Astrocytoma:

9 (show top 50) (show all 2015)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10672 TP53 central nervous system,cerebrum,glioma,astrocytoma Grade II c.577C>T p.H193Y 5
2 COSM40802 ZW10 central nervous system,brain,glioma,astrocytoma Grade III c.2140C>T p.P714S 4
3 COSM40801 ZSWIM4 central nervous system,brain,glioma,astrocytoma Grade III c.266C>T p.P89L 4
4 COSM39611 ZPLD1 central nervous system,brain,glioma,astrocytoma Grade III c.393A>T p.G131G 4
5 COSM40237 ZNF687 central nervous system,brain,glioma,astrocytoma Grade III c.3651C>T p.T1217T 4
6 COSM39318 ZNF687 central nervous system,brain,glioma,astrocytoma Grade III c.2044T>A p.C682S 4
7 COSM39317 ZNF687 central nervous system,brain,glioma,astrocytoma Grade III c.2043G>C p.Q681H 4
8 COSM39149 ZNF507 central nervous system,brain,glioma,astrocytoma Grade III c.1517G>C p.R506T 4
9 COSM40794 ZNF473 central nervous system,brain,glioma,astrocytoma Grade III c.42C>T p.D14D 4
10 COSM39217 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade III c.2162T>G p.V721G 4
11 COSM40504 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade III c.2176G>A p.D726N 4
12 COSM39507 ZMAT4 central nervous system,brain,glioma,astrocytoma Grade III c.76G>A p.E26K 4
13 COSM40870 ZFC3H1 central nervous system,brain,glioma,astrocytoma Grade III c.1055G>A p.S352N 4
14 COSM40793 ZFAT central nervous system,brain,glioma,astrocytoma Grade III c.1006G>A p.V336M 4
15 COSM40680 ZEB1 central nervous system,brain,glioma,astrocytoma Grade III c.1913C>T p.S638L 4
16 COSM41152 ZC3H6 central nervous system,brain,glioma,astrocytoma Grade III c.2254G>T p.G752* 4
17 COSM40778 ZBTB4 central nervous system,brain,glioma,astrocytoma Grade III c.2842C>T p.L948F 4
18 COSM40777 ZBTB24 central nervous system,brain,glioma,astrocytoma Grade III c.1886C>T p.P629L 4
19 COSM39508 ZBTB21 central nervous system,brain,glioma,astrocytoma Grade III c.997G>A p.G333S 4
20 COSM40776 ZBTB16 central nervous system,brain,glioma,astrocytoma Grade III c.413C>T p.A138V 4
21 COSM41039 YWHAH central nervous system,brain,glioma,astrocytoma Grade III c.169C>T p.R57* 4
22 COSM40774 YTHDC2 central nervous system,brain,glioma,astrocytoma Grade III c.782C>T p.A261V 4
23 COSM39272 XPO7 central nervous system,brain,glioma,astrocytoma Grade III c.1157G>A p.R386Q 4
24 COSM40772 XPO1 central nervous system,brain,glioma,astrocytoma Grade III c.1147G>A p.E383K 4
25 COSM21780 XAB2 central nervous system,brain,glioma,astrocytoma Grade III c.849C>A p.I283I 4
26 COSM39469 WNK2 central nervous system,brain,glioma,astrocytoma Grade III c.3757G>A p.A1253T 4
27 COSM40770 WNK1 central nervous system,brain,glioma,astrocytoma Grade III c.5293G>A p.G1765S 4
28 COSM40769 WFS1 central nervous system,brain,glioma,astrocytoma Grade III c.573G>A p.K191K 4
29 COSM40767 WEE1 central nervous system,brain,glioma,astrocytoma Grade III c.765G>A p.K255K 4
30 COSM40766 WDTC1 central nervous system,brain,glioma,astrocytoma Grade III c.1118C>T p.A373V 4
31 COSM40765 WDR70 central nervous system,brain,glioma,astrocytoma Grade III c.463G>A p.E155K 4
32 COSM40764 WDR6 central nervous system,brain,glioma,astrocytoma Grade III c.1170C>T p.F390F 4
33 COSM40761 WDR34 central nervous system,brain,glioma,astrocytoma Grade III c.1484C>T p.T495I 4
34 COSM40762 WDR34 central nervous system,brain,glioma,astrocytoma Grade III c.475G>A p.A159T 4
35 COSM39468 WDR24 central nervous system,brain,glioma,astrocytoma Grade III c.790C>T p.R264C 4
36 COSM40758 WDFY3 central nervous system,brain,glioma,astrocytoma Grade III c.1126C>T p.H376Y 4
37 COSM39888 WBP1L central nervous system,brain,glioma,astrocytoma Grade III c.490C>T p.P164S 4
38 COSM40234 WASHC4 central nervous system,brain,glioma,astrocytoma Grade III c.367+1G>A p.? 4
39 COSM40754 VPS45 central nervous system,brain,glioma,astrocytoma Grade III c.370G>A p.E124K 4
40 COSM40753 VPS41 central nervous system,brain,glioma,astrocytoma Grade III c.1830G>A p.Q610Q 4
41 COSM39977 VPS13B central nervous system,brain,glioma,astrocytoma Grade III c.1913C>T p.T638I 4
42 COSM41129 VPS13B central nervous system,brain,glioma,astrocytoma Grade III c.9845A>C p.K3282T 4
43 COSM40751 VPS13A central nervous system,brain,glioma,astrocytoma Grade III c.7400G>A p.G2467D 4
44 COSM40750 VN2R1P central nervous system,brain,glioma,astrocytoma Grade III c.1753C>T p.P585S 4
45 COSM40748 VIPR2 central nervous system,brain,glioma,astrocytoma Grade III c.598G>A p.V200M 4
46 COSM39478 VIPAS39 central nervous system,brain,glioma,astrocytoma Grade III c.1200G>C p.K400N 4
47 COSM39246 VEGFD central nervous system,brain,glioma,astrocytoma Grade III c.694A>G p.K232E 4
48 COSM40746 VDR central nervous system,brain,glioma,astrocytoma Grade III c.1135C>T p.L379F 4
49 COSM40744 VCPIP1 central nervous system,brain,glioma,astrocytoma Grade III c.3601G>A p.E1201K 4
50 COSM40745 VCL central nervous system,brain,glioma,astrocytoma Grade III c.1369C>T p.P457S 4

Copy number variations for Astrocytoma from CNVD:

7 (show top 50) (show all 436)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13337 1 1 124300000 Loss Astrocytoma
2 13347 1 1 125000000 Deletion Astrocytoma
3 13376 1 1 2300000 Amplification AURKAIP1 Astrocytoma
4 13377 1 1 2300000 Amplification C1orf159 Astrocytoma
5 13378 1 1 2300000 Amplification CDC2L1 Astrocytoma
6 13379 1 1 2300000 Amplification CDC2L2 Astrocytoma
7 13380 1 1 2300000 Amplification CPSF3L Astrocytoma
8 13381 1 1 2300000 Amplification GNB1 Astrocytoma
9 13382 1 1 2300000 Amplification HES4 Astrocytoma
10 13383 1 1 2300000 Amplification ISG15 Astrocytoma
11 13386 1 1 2300000 Amplification MIB2 Astrocytoma
12 13387 1 1 2300000 Amplification MMP23A Astrocytoma
13 13388 1 1 2300000 Amplification NOC2L Astrocytoma
14 13389 1 1 2300000 Amplification PRKCZ Astrocytoma
15 13390 1 1 2300000 Amplification SDF4 Astrocytoma
16 13391 1 1 2300000 Amplification SLC35E2 Astrocytoma
17 13757 1 1 28000000 Deletion Astrocytoma
18 13760 1 1 28000000 Deletion Astrocytoma
19 16428 1 124300000 247249719 Gain Astrocytoma
20 16544 1 12700000 16200000 Deletion Astrocytoma
21 30468 1 243700000 249250621 Deletion AKT3 Astrocytoma
22 30469 1 243700000 249250621 Deletion SDCCAG8 Astrocytoma
23 30470 1 243700000 249250621 Deletion ZNF238 Astrocytoma
24 31970 1 32400000 34600000 Deletion Astrocytoma
25 32218 1 34600000 44100000 Deletion Astrocytoma
26 35014 1 59000000 68900000 Deletion Astrocytoma
27 36950 1 8384389 8404226 Deletion SLC45A1 Astrocytoma
28 46536 10 82000000 135374737 Loss Astrocytoma
29 48496 11 1 52900000 Loss Astrocytoma
30 67045 12 35400000 132349534 Loss Astrocytoma
31 67785 12 44600000 69800000 Gain Astrocytoma
32 75152 13 16000000 114142980 Loss Astrocytoma
33 89238 15 17000000 100338915 Gain Astrocytoma
34 97277 16 1 38200000 Loss Astrocytoma
35 97302 16 1 6300000 Amplification ABCA3 Astrocytoma
36 97303 16 1 6300000 Amplification AXIN1 Astrocytoma
37 97304 16 1 6300000 Amplification C1QTNF8 Astrocytoma
38 97305 16 1 6300000 Amplification CACNA1H Astrocytoma
39 97306 16 1 6300000 Amplification CREBBP Astrocytoma
40 97307 16 1 6300000 Amplification DNAJA3 Astrocytoma
41 97308 16 1 6300000 Amplification HMOX2 Astrocytoma
42 97309 16 1 6300000 Amplification IGFALS Astrocytoma
43 97310 16 1 6300000 Amplification MAGMAS Astrocytoma
44 97311 16 1 6300000 Amplification MAPK8IP3 Astrocytoma
45 97312 16 1 6300000 Amplification MMP25 Astrocytoma
46 97313 16 1 6300000 Amplification MPG Astrocytoma
47 97314 16 1 6300000 Amplification MRPL28 Astrocytoma
48 97315 16 1 6300000 Amplification MSLN Astrocytoma
49 97316 16 1 6300000 Amplification NME4 Astrocytoma
50 97317 16 1 6300000 Amplification NTHL1 Astrocytoma

Expression for Astrocytoma

Search GEO for disease gene expression data for Astrocytoma.

Pathways for Astrocytoma

Pathways related to Astrocytoma according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 CCND1 CDK4 CDKN2A EGFR GFAP ITGB1
2
Show member pathways
13.1 EGFR ITGB1 KRAS MDM2 PTEN TP53
3
Show member pathways
12.95 CCND1 EGFR ITGB1 KRAS PTEN VEGFA
4
Show member pathways
12.83 ITGB1 KRAS PTEN TP53 VEGFA
5
Show member pathways
12.83 CCND1 EGFR ITGB1 KRAS PTEN VEGFA
6
Show member pathways
12.76 EGFR ITGB1 KRAS NF1 VEGFA
7
Show member pathways
12.76 EGFR KRAS MDM2 PTEN TP53
8
Show member pathways
12.72 CCND1 CDK4 MDM2 MGMT TP53
9 12.68 CCND1 CDK4 EGFR ITGB1 KRAS MDM2
10
Show member pathways
12.63 CCND1 CDK4 CDKN2A MDM2 TP53
11 12.62 CCND1 CDK4 CDKN2A EGFR ITGB1 KRAS
12 12.56 CCND1 CDK4 CDKN2A MDM2 MGMT TP53
13
Show member pathways
12.54 EGFR KRAS MDM2 TP53
14
Show member pathways
12.51 EGFR ITGB1 KRAS MDM2 TP53
15 12.51 CCND1 CDKN2A EGFR KRAS MDM2 PTEN
16 12.49 CCND1 CDK4 CDKN2A KRAS TP53
17
Show member pathways
12.49 CCND1 CDK4 EGFR ITGB1 KRAS
18
Show member pathways
12.46 CCND1 CDK4 CDKN2A EGFR ITGB1 KRAS
19 12.43 CCND1 CDK4 CDKN2A MDM2 TP53
20
Show member pathways
12.42 CCND1 MDM2 PTEN TP53
21
Show member pathways
12.4 CCND1 CDK4 CDKN2A MDM2 PTEN TP53
22
Show member pathways
12.39 CCND1 CDK4 CDKN2A TP53
23
Show member pathways
12.37 CCND1 EGFR KRAS MDM2 TP53
24
Show member pathways
12.31 CCND1 CDK4 MDM2 PTEN TP53
25 12.31 CCND1 EGFR ITGB1 KRAS MDM2 TP53
26 12.3 CCND1 CDK4 CDKN2A KRAS MDM2 TP53
27
Show member pathways
12.29 EGFR ITGB1 KRAS PTEN VEGFA
28 12.25 CCND1 EGFR KRAS TP53 VEGFA
29
Show member pathways
12.22 CCND1 CDK4 EGFR ITGB1 KRAS MDM2
30
Show member pathways
12.17 CCND1 EGFR MDM2 PTEN
31
Show member pathways
12.14 CCND1 EGFR KRAS MDM2 PTEN
32 12.12 EGFR MDM2 PTEN TP53
33
Show member pathways
12.11 CCND1 CDK4 EGFR KRAS NF1
34 12.1 CDKN2A MDM2 TP53 VEGFA
35 12.06 CCND1 KRAS MDM2 TP53
36 12.05 CCND1 ITGB1 TP53 VEGFA
37 12.04 CCND1 CDK4 EGFR GFAP TP53
38
Show member pathways
12.02 EGFR GFAP KRAS MDM2
39 12.01 CDKN2A MDM2 PTEN TP53
40